Aquestive Therapeutics, Inc. develops and commercializes innovative pharmaceutical products using its proprietary PharmFilm technology, focusing on central nervous system disorders and other therapeutic areas. On June 25, 2026, with the market open, AQST shares traded at $4.2750, down 14.33% from the prior session's close of $4.9900. The decline reflects selling pressure without an immediate identifiable news trigger, as the stock pulled back from recent gains.
Trading volume exceeded the average, indicating heightened investor activity. The selloff aligned with softer sentiment across select small-cap healthcare peers, though major indices showed mixed performance. Technical levels near recent support were tested as the price moved lower intraday.
The drop took place against a backdrop of variable performance in the specialty pharmaceuticals sector. While AQST had benefited earlier from positive clinical and financing updates, today's action appeared driven more by profit-taking and general risk-off flows in smaller biotech and pharma names rather than any fundamental shift in the company's outlook.
Tickeron’s Trending AI Robots page highlights the strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with only the top performers featured in this curated section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade. Investors seeking automated trading insights can explore the platform for additional tools and strategies.
Investors will watch for regulatory progress on the Anaphylm sublingual film NDA resubmission targeted for the third quarter. The company is also expected to report second-quarter results around August 11. Key risks include clinical development timelines, regulatory decisions, and ongoing cash burn typical of development-stage biopharma firms. Market participants will continue to assess sector sentiment and any new corporate announcements.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AQST broke above its upper Bollinger Band on June 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In of the 41 cases the stock fell afterwards. This puts the odds of success at .
The 10-day RSI Indicator for AQST moved out of overbought territory on June 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AQST as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AQST turned negative on June 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQST declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
AQST moved above its 50-day moving average on July 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AQST crossed bullishly above the 50-day moving average on June 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AQST advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 186 cases where AQST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (46.452). P/E Ratio (0.000) is within average values for comparable stocks, (99.681). AQST's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.697). AQST has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (9.597) is also within normal values, averaging (114.852).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AQST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer thin film pharmaceutical and over the counter drug products
Industry PharmaceuticalsGeneric